Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Pharmanest AB
DescriptionTopical 4% formulation of lidocaine
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat pain associated with hysteroscopies; Treat pain associated with intrauterine device (IUD) insertion
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today